Ohsu Hospital And Clinics
- Type
- Teaching hospital
- Where
- Portland, OR
- Medicare CCN
- 380009
- Received
- $37,353,933 in 3,071 records, 2020 ($2,700,926 general, $34,653,006 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 212 | $2,700,926 |
| 2020 | Research payment | 2,859 | $34,653,006 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,859 | $34,653,006 |
| Grant | 37 | $1,993,661 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 83 | $371,216 |
| Royalty or License | 30 | $126,055 |
| Consulting Fee | 4 | $110,177 |
| Space rental or facility fees (teaching hospital only) | 29 | $61,129 |
| Education | 6 | $26,566 |
| Gift | 19 | $9,662 |
| Charitable Contribution | 3 | $1,708 |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing educat | 1 | $750 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Gilead Sciences, Inc. | $149,967 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $15,834 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $7,397 | Research payment | Cash or cash equivalent | OHSU2018MRIPR853Rooney | 2020 | |
| 2020-12-31 | Blueprint Medicines Corporation | $7,182 | Research payment | Cash or cash equivalent | BLU-667-1101 | 2020 | |
| 2020-12-31 | ABBVIE INC. | $5,792 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-12-31 | Ultragenyx Pharmaceutical Inc. | $5,170 | Research payment | Cash or cash equivalent | DOJOLVI Drug, Oral nutritional supplements | UX007-CL003 | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $4,734 | Research payment | Cash or cash equivalent | OHSU2019MRIPR711Fair | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $4,125 | Research payment | Cash or cash equivalent | OHSU2018MRIPR932IPR991Schabel | 2020 | |
| 2020-12-31 | Acerta Pharma LLC | $3,561 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Proof of Concept Study of the Combination of ACP196 and ACP319 in Subjects with Bcell Malignancies | 2020 |
| 2020-12-31 | Acerta Pharma LLC | $3,205 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,236 | Research payment | Cash or cash equivalent | OHSU2020MRIPR944Stevens | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | OHSU2019MRiPR758Rooney | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $411 | Research payment | Cash or cash equivalent | OHSU2018MRIPR816Kroenke | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $405 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $375 | Research payment | Cash or cash equivalent | OHSU2018MRIPR919Kroenke | 2020 | |
| 2020-12-31 | Masimo Corporation | $181 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-31 | Masimo Corporation | $181 | Education | In-kind items and services | SedLine Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $92 | Research payment | Cash or cash equivalent | OHSU2018MRIPR838Kroenke | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $22 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $21 | Research payment | Cash or cash equivalent | OHSU2018MRIPR1055Kroenke | 2020 | |
| 2020-12-30 | Dexcom, Inc. | $319,536 | Research payment | Cash or cash equivalent | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | TIME-IN-RANGE USING CGM MANAGEMENT OF GDM | 2020 |
| 2020-12-30 | ABBVIE INC. | $12,564 | Research payment | Cash or cash equivalent | M15-570 | 2020 | |
| 2020-12-30 | ABBVIE INC. | $10,510 | Research payment | Cash or cash equivalent | M15-566 | 2020 | |
| 2020-12-30 | Merck Sharp & Dohme LLC | $9,283 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2020 |
| 2020-12-30 | ABBVIE INC. | $8,945 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-531 | 2020 |
| 2020-12-30 | ABBVIE INC. | $6,827 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-045 | 2020 |
| 2020-12-30 | ABBVIE INC. | $6,366 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-654 | 2020 |
| 2020-12-30 | ABBVIE INC. | $3,044 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M19-850 | 2020 |
| 2020-12-30 | ABBVIE INC. | $2,755 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | M14-702 | 2020 |
| 2020-12-30 | ABBVIE INC. | $2,360 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-522 | 2020 |
| 2020-12-30 | ABBVIE INC. | $1,823 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M16-049 | 2020 |
| 2020-12-30 | Incyte Corporation | $500 | Research payment | Cash or cash equivalent | A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroid | 2020 | |
| 2020-12-29 | Incyte Corporation | $45,938 | Research payment | Cash or cash equivalent | A Phase II trial of INCMGA00012 in patients with previously treated advanced or metastatic adenosquamous pancreatic canc | 2020 | |
| 2020-12-29 | Otsuka Pharmaceutical Co., Ltd. | $2,482 | Research payment | Cash or cash equivalent | AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN PRIOR CLINICAL STUDIES OF ASTX727 (STANDARD | 2020 | |
| 2020-12-29 | Otsuka Pharmaceutical Co., Ltd. | $1,153 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, OPEN-LABEL, CORSSOVER STUDY OF ASTX727 (CEDAZURIDINE AND DECITABINE FIXED-DOSE COMBINATION) VERSU | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-29 | Tandem Diabetes Care, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-28 | BeiGene, Ltd. | $64,380 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patient | 2020 |
| 2020-12-28 | BeiGene, Ltd. | $39,043 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated Chronic Lymphocy | 2020 |
| 2020-12-24 | Strongbridge US INC. | $14,250 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $3,818 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $3,238 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $3,110 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $3,000 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,986 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,813 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,813 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,295 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,214 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,161 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $2,094 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,684 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $1,152 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Strongbridge US INC. | $460 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-24 | Strongbridge US INC. | $460 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-24 | Strongbridge US INC. | $460 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $415 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $415 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2020 |
| 2020-12-24 | Strongbridge US INC. | $412 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $250 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Deciphera Pharmaceuticals Inc. | $153 | Research payment | Cash or cash equivalent | STUDY OF DCC-3014 IN PATIENTS WITH ADVANCED TUMORS AND TENOSYNOVIAL GIANT CELL TUMOR | 2020 | |
| 2020-12-24 | Strongbridge US INC. | $60 | Research payment | Cash or cash equivalent | A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Ef | 2020 | |
| 2020-12-23 | Kite Pharma, Inc. | $35,445 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 1/2 Open-Label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects with Relapsed or Refract | 2020 |
| 2020-12-23 | Edwards Lifesciences Corporation | $1,190 | Research payment | Cash or cash equivalent | CLASP IIF (2018-07) | 2020 | |
| 2020-12-22 | Genentech, Inc. | $25,430 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2020 |
| 2020-12-22 | Merck Sharp & Dohme LLC | $12,522 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-12-22 | SEAGEN INC. | $9,349 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2020 |
| 2020-12-22 | Novo Nordisk AS | $8,694 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-22 | Incyte Corporation | $4,323 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $3,100 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat | 2020 |
| 2020-12-22 | Daiichi Sankyo Inc. | $2,713 | Research payment | Cash or cash equivalent | Enhertu Drug, Oncology | DS8201-A-U303 | 2020 |
| 2020-12-22 | Incyte Corporation | $1,971 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | Merck Sharp & Dohme LLC | $1,360 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2020 |
| 2020-12-22 | Amgen Inc. | $1,185 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-12-22 | Novo Nordisk AS | $800 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-22 | Boston Scientific Corporation | $650 | Research payment | Cash or cash equivalent | EKOSONIC Device, PERIPHERAL VASCULAR | KNOCOUT PE | 2020 |
| 2020-12-22 | Incyte Corporation | $484 | Research payment | Cash or cash equivalent | A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatin | 2020 | |
| 2020-12-22 | SEAGEN INC. | $205 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-21 | Edwards Lifesciences Corporation | $19,179 | Research payment | Cash or cash equivalent | CLASP IID 2018-07 | 2020 | |
| 2020-12-21 | Eli Lilly and Company | $13,800 | Research payment | Cash or cash equivalent | A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VAN | 2020 | |
| 2020-12-21 | Janssen Research & Development, LLC | $3,215 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-12-18 | Incyte Corporation | $181,350 | Research payment | Cash or cash equivalent | Prospective Evaluation for CNL aCML with Mutation of CSF3R Knight Cancer Inst, Oregon Health Sci Univ | 2020 | |
| 2020-12-18 | JAZZ PHARMACEUTICALS INC. | $169,372 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-12-18 | PFIZER INC. | $134,048 | Research payment | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | PRACTICAL STRATEGIES TO SCREEN FOR TRANSTHYRETIN AMYLOID CARDIOMYOPATHY IN PATIENTS WITH AORTIC STENOSIS | 2020 |
| 2020-12-18 | Pharmacyclics LLC, an AbbVie Company | $2,346 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1146-IM | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $384 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $237 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-12-17 | Deciphera Pharmaceuticals Inc. | $576,000 | Research payment | In-kind items and services | QINLOCK Drug, ONCOLOGY | INVICTUS A PHASE 3 INTERVENTIONAL DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF DCC-2618 IN | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $116,005 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Blueprint Medicines Corporation | $65,796 | Research payment | Cash or cash equivalent | BLU-285-1101 | 2020 | |
| 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | $29,524 | Research payment | Cash or cash equivalent | A PHASE 1-2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF ASTX029 IN SUBJECTS WITH ADVANCED SOLID TUMORS | 2020 | |
| 2020-12-17 | Exelixis Inc. | $28,440 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $23,574 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $19,541 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $3,495 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | $2,765 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PHASE 1-2 STUDY OF ASTX727 LOW DOSE (ASTX727 LD) EXTENDED SCHEDULE IN SUBJECTS WITH LOWER RISK | 2020 | |
| 2020-12-17 | Edwards Lifesciences Corporation | $2,316 | Research payment | Cash or cash equivalent | EVOQUE TR 2019-06 | 2020 | |
| 2020-12-17 | Exelixis Inc. | $1,620 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Exelixis Inc. | $1,491 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2020 |
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $1,060 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYP | 2020 | |
| 2020-12-17 | Eli Lilly and Company | $910 | Research payment | In-kind items and services | CYCLONE 1: A PHASE 2 STUDY OF ABEMACICLIB IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED | 2020 | |
| 2020-12-17 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | MitraClip Device, Vascular | Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitr | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $450 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $450 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $420 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $255 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $255 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Medicines360 | $148 | Research payment | Cash or cash equivalent | Liletta Device, Obstetrics/Gynecology (Women's Health) | A Phase 3 multicenter, open-label study of a Levonorgestrel 52 mg Intrauterine System for the treatment of heavy Menstru | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Travere Therapeutics, Inc. | $145 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | Protocol No: 018CTXX15001 | 2020 |
| 2020-12-17 | Novo Nordisk AS | $25 | Research payment | In-kind items and services | Wegovy Drug, Diabetes | EX9536-4388 | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $24,293 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Ax | 2020 |
| 2020-12-16 | Merck Sharp & Dohme LLC | $13,789 | Research payment | Cash or cash equivalent | MK-6482 Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2020 |
| 2020-12-16 | Genentech, Inc. | $3,915 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PORT DELIVERY SYSTEM OF RANIZIBUMAB EXTENSION STUDY | 2020 |
| 2020-12-16 | Zimmer Biomet Holdings, Inc. | $2,750 | Grant | Cash or cash equivalent | Grants Device, General | 2020 | |
| 2020-12-16 | KLS-Martin L.P. | $2,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | KLS-Martin L.P. | $750 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-16 | Tandem Diabetes Care, Inc. | $425 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $367 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine,Cisplatin versus Placebo Plus Gemcitabine,Cis | 2020 |
| 2020-12-16 | Tandem Diabetes Care, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-16 | Tandem Diabetes Care, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-16 | Tandem Diabetes Care, Inc. | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t:slim X2 insulin pump Device, Endocrinology | 2020 | |
| 2020-12-15 | E.R. Squibb & Sons, L.L.C. | $19,435 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase III 1L Combo SCLC Consolidation LD ED non-progressors | 2020 |
| 2020-12-15 | ABBVIE INC. | $12,353 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M15-531 | 2020 |
| 2020-12-15 | Exelixis Inc. | $5,379 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $4,556 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Biogen, Inc. | $4,380 | Research payment | Cash or cash equivalent | A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial of Re | 2020 | |
| 2020-12-15 | Mallinckrodt Hospital Products Inc. | $3,789 | Research payment | Cash or cash equivalent | AN OPEN LABEL EXPANDED ACCESS TREATMENT PROTOCOL FOR VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN PATIENTS WITH NEUROLOGI | 2020 | |
| 2020-12-15 | Exelixis Inc. | $3,000 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $2,404 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,857 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | ABBVIE INC. | $1,722 | Research payment | Cash or cash equivalent | M14-064 | 2020 | |
| 2020-12-15 | Exelixis Inc. | $1,500 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,351 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | BeiGene, Ltd. | $1,296 | Research payment | Cash or cash equivalent | BRUKINSA Drug, ONCOLOGY | An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patient | 2020 |
| 2020-12-15 | Amgen Inc. | $1,185 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,141 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | Exelixis Inc. | $1,072 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-15 | E.R. Squibb & Sons, L.L.C. | $510 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB Signal Detection Single arm, PD-1 TNBC, SCLC, pancreatic, gastric, bladder, Ovarian Mono and Combo | 2020 |
| 2020-12-15 | Exelixis Inc. | $300 | Research payment | Cash or cash equivalent | Cabozantinib Drug, Oncology | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 2020 |
| 2020-12-14 | SEAGEN INC. | $45,451 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-12-14 | Merck Sharp & Dohme LLC | $26,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $17,346 | Research payment | Cash or cash equivalent | TREMFYA Drug, Immunology | An open label pilot trial of guselkumab in the treatment of adults with pityriasis rubra pilaris (PRP) | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $12,698 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-14 | SANOFI US SERVICES INC. | $10,136 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With G | 2020 | |
| 2020-12-14 | Medical Device Business Services, Inc. | $8,922 | Research payment | Cash or cash equivalent | EMBOTRAP II Revascularization Device Device, Neurovascular | Embotrap extraction & Clot Evaluation & Lesion Evaluation for Neurothrombectomy | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $6,558 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $1,470 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-14 | Janssen Research & Development, LLC | $690 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-14 | Merck Sharp & Dohme LLC | $607 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Do | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $362 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-14 | Merck Sharp & Dohme LLC | $253 | Research payment | In-kind items and services | IMPLANON Drug, WOMENS HEALTH | A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $88 | Research payment | Cash or cash equivalent | Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus | 2020 | |
| 2020-12-12 | Novo Nordisk AS | $90,501 | Research payment | Cash or cash equivalent | 2020 | ||
| 2020-12-11 | Amgen Inc. | $51,001 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Study of Apremilast in Subjects With Moderate to Severe Genital Psoriasis(PSOR-025) | 2020 |
| 2020-12-11 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in | 2020 |
| 2020-12-11 | Incyte Corporation | $22,234 | Research payment | Cash or cash equivalent | A Randomized, Double Blind, Placebo Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroid | 2020 | |
| 2020-12-11 | E.R. Squibb & Sons, L.L.C. | $5,291 | Research payment | Cash or cash equivalent | OPDIVO Biological, Oncology | Phase IIB TMB High Pan Tumor FA for tTMB | 2020 |
| 2020-12-11 | E.R. Squibb & Sons, L.L.C. | $3,093 | Research payment | Cash or cash equivalent | Ph I IIA FIH mono& combo Tx Solid Tumor | 2020 | |
| 2020-12-11 | W. L. Gore & Associates, Inc. | $2,985 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch an | 2020 |
| 2020-12-11 | Janssen Research & Development, LLC | $2,758 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk | 2020 | |
| 2020-12-10 | AstraZeneca Pharmaceuticals LP | $176,057 | Research payment | Cash or cash equivalent | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-12-10 | Mallinckrodt Hospital Products Inc. | $3,789 | Research payment | Cash or cash equivalent | AN OPEN LABEL EXPANDED ACCESS TREATMENT PROTOCOL FOR VTS-270 (2-HYDROXYPROPYL-?-CYCLODEXTRIN) IN PATIENTS WITH NEUROLOGI | 2020 | |
| 2020-12-10 | Spark Therapeutics, Inc. | $2,592 | Research payment | Cash or cash equivalent | A MULTI-CENTER EVALUATION OF THE LONG-TERM SAFETY AND EFFICACY OF SPK-8011 [ADENO-ASSOCIATED VIRAL VECTOR WITH B-DOMAIN | 2020 | |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,513 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF EVINACUMAB IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYP | 2020 | |
| 2020-12-10 | Aesculap, Inc. | $1,294 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $1,063 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | MED-EL Corporation | $883 | Research payment | Cash or cash equivalent | MED-EL Maestro Cochlear Implant System Device, Cochlear implant | Evaluating and Optimizing Electrically-Evoked Stapedial Reflex Threshold (eSRT) Measurements in Adult Cochlear Implant R | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $714 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-10 | Novo Nordisk AS | $400 | Research payment | Cash or cash equivalent | EX9536-4388 | 2020 | |
| 2020-12-10 | Aesculap, Inc. | $395 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Aesculap, Inc. | $352 | Gift | Cash or cash equivalent | 2020 |
The latest 200 records of 3,071.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Portland, OR, county Multnomah County, OR, state Oregon; placed by its city name.
| Measure | Place (city or town) Portland, OR | County Multnomah County, OR | State Oregon |
|---|---|---|---|
| Population B01003 | 641,165 | 801,477 | 4,254,293 |
| Population, 2020 census P1 | 652,503 | 815,428 | 4,237,256 |
| Median age B01002 | 38.8 | 38.7 | 40.4 |
| Under 18 B01001 | 16.3% | 17.6% | 19.9% |
| 65 and over B01001 | 14.5% | 14.8% | 19.1% |
| Households B11001 | 289,705 | 349,803 | 1,718,422 |
| Foreign born B05002 | 12.4% | 13.0% | 9.8% |
| Median household income B19013 | $90,919 | $88,766 | $83,011 |
| Median family income B19113 | $124,706 | $118,358 | $102,281 |
| Per capita income B19301 | $57,029 | $53,996 | $45,612 |
| Poverty rate B17001 | 12.7% | 12.6% | 11.9% |
| Unemployment rate B23025 | 5.8% | 5.7% | 5.4% |
| Civilian labor force B23025 | 387,826 | 471,313 | 2,183,462 |
| Mean commute (minutes) B08013 | 24.1 | 24.4 | 23.0 |
| Bachelor's degree or higher B15003 | 53.8% | 48.9% | 36.8% |
| Housing units B25001 | 307,719 | 371,179 | 1,857,992 |
| Owner-occupied B25003 | 52.0% | 53.4% | 63.3% |
| Renters B25003 | 48.0% | 46.6% | 36.7% |
| Median home value B25077 | $581,500 | $552,700 | $477,600 |
| Median gross rent B25064 | $1,655 | $1,646 | $1,525 |
| White, not Hispanic B03002 | 65.8% | 65.2% | 71.4% |
| Black B03002 | 5.5% | 5.3% | 1.8% |
| Hispanic or Latino B03002 | 12.0% | 13.5% | 14.7% |
| Asian B03002 | 8.0% | 7.4% | 4.4% |
| American Indian and Alaska Native B03002 | 0.4% | 0.4% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Portland, OR.
Comments